Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.

@article{Ezekowitz2016ApixabanCW,
  title={Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.},
  author={Michael David Ezekowitz and Charles V. Pollack and Paul W Sanders and Jonathan L. Halperin and Judith Spahr and Nilo B. Cater and William Petkun and Andrei Breazna and Paulus Kirchhof and Jonas Oldgren},
  journal={American heart journal},
  year={2016},
  volume={179},
  pages={
          59-68
        }
}
BACKGROUND Stroke prevention in anticoagulation-naïve patients with atrial fibrillation undergoing cardioversion has not been systematically studied. OBJECTIVE To determine outcomes in anticoagulation-naïve patients (defined as those receiving an anticoagulant for <48 hours during the index episode of atrial fibrillation) scheduled for cardioversion. METHODS This is a randomized, prospective, open-label, real-world study comparing apixaban to heparin plus warfarin. Early image-guided… CONTINUE READING
BETA
7
Twitter Mentions

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

Möglichkeiten und Herausforderungen in der oralen Antikoagulation

oralen Antikoagulation, Miklos Rohla
  • 2019
VIEW 4 EXCERPTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES